Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
J.J.M. Kwakman & C.J.A. Punt. (2016) Oral drugs in the treatment of metastatic colorectal cancer. Expert Opinion on Pharmacotherapy 17:10, pages 1351-1361.
Read now
Read now
Hiroshi Yasui, Giichiro Tsurita & Kohzoh Imai. (2014) DNA synthesis inhibitors for the treatment of gastrointestinal cancer. Expert Opinion on Pharmacotherapy 15:16, pages 2361-2372.
Read now
Read now
Masaaki Kawahara. (2014) Efficacy of S-1 in non-small cell lung cancer. Expert Opinion on Pharmacotherapy 15:13, pages 1927-1942.
Read now
Read now
Kristin Landis-Piwowar, Di Chen, Robert Foldes, Tak-Hang Chan & Qing Ping Dou. (2013) Novel epigallocatechin gallate analogs as potential anticancer agents: a patent review (2009 – present). Expert Opinion on Therapeutic Patents 23:2, pages 189-202.
Read now
Read now
Articles from other publishers (27)
Mai Seki, Takaaki Sano, Masaru Ogawa, Yu Takayama, Satoshi Yokoo & Tetsunari Oyama. (2023) Relationship between histopathological therapeutic effect and prognosis in oral cancer patients after preoperative S-1 chemotherapy followed by surgery. Clinical Oral Investigations 27:8, pages 4817-4826.
Crossref
Crossref
Li Tu, Weihan Zhang, Lu Ni, Zihan Xu, Kun Yang, Hongfeng Gou, Qing Zhu, Ming Liu, Yu Yang, Jiankun Hu & Meng Qiu. (2022)
Study of
SOX
combined with intraperitoneal high‐dose paclitaxel in gastric cancer with synchronous peritoneal metastasis: A phase
II
single‐arm clinical trial
. Cancer Medicine 12:4, pages 4161-4169.
Crossref
Crossref
Yujiro Nishizawa, Naotsugu Haraguchi, Hirotoshi Kim, Yoshihito Ide, Ken Nakata, Shu Okamura, Toshihiro Kudo, Taroh Satoh, Mamoru Uemura, Chu Matsuda, Tsunekazu Mizushima, Kohei Murata, Yuichiro Doki & Hidetoshi Eguchi. (2021) Randomized phase II study of SOX+B-mab versus SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study). BMC Cancer 21:1.
Crossref
Crossref
Yoshihiko Nakamoto, Masafumi Noda, Ryuichi Mikami, Yukihiko Tokunaga, Tatsuo Okumoto, Takashi Kawamura, Hidetoshi Fujiwara, Sadayuki Doi & Naohiro Tomita. (2020) Phase II study of S-1-based sequential combination chemotherapy including oxaliplatin plus bevacizumab and irinotecan with or without cetuximab for metastatic colorectal cancer: the SOBIC trial. International Journal of Clinical Oncology 25:7, pages 1285-1290.
Crossref
Crossref
Eiji Sunami, Tetsuya Kusumoto, Mitsuyoshi Ota, Yoshiyuki Sakamoto, Kazuhiro Yoshida, Naohiro Tomita, Atsuyuki Maeda, Jin Teshima, Michio Okabe, Chihiro Tanaka, Junichiro Yamauchi, Michio Itabashi, Kenjiro Kotake, Keiichi Takahashi, Hideo Baba, Narikazu Boku, Keisuke Aiba, Megumi Ishiguro, Satoshi Morita, Naruhito Takenaka, Ryota Okude & Kenichi Sugihara. (2020) S-1 and Oxaliplatin Versus Tegafur-uracil and Leucovorin as Postoperative Adjuvant Chemotherapy in Patients With High-risk Stage III Colon Cancer (ACTS-CC 02): A Randomized, Open-label, Multicenter, Phase III Superiority Trial. Clinical Colorectal Cancer 19:1, pages 22-31.e6.
Crossref
Crossref
Long Yan, Hongbin Liu, Hongtao Li, Xiaopeng Han, Tingbao Cao, Chaoyang Wang & Gaitian Li. (2019) The efficacy and feasibility of adopting intravenous chemotherapy and oral S-1 as a sequential therapy for postoperative gastric cancer patients. Medicine 98:44, pages e17605.
Crossref
Crossref
Tetsuya Kusumoto, Eiji Sunami, Mitsuyoshi Ota, Kazuhiro Yoshida, Yoshiyuki Sakamoto, Naohiro Tomita, Atsuyuki Maeda, Izumi Mochizuki, Michio Okabe, Katsuyuki Kunieda, Junichiro Yamauchi, Michio Itabashi, Kenjiro Kotake, Keiichi Takahashi, Hideo Baba, Narikazu Boku, Keisuke Aiba, Megumi Ishiguro, Satoshi Morita & Kenichi Sugihara. (2018) Planned Safety Analysis of the ACTS-CC 02 Trial: A Randomized Phase III Trial of S-1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High-Risk Stage III Colon Cancer. Clinical Colorectal Cancer 17:2, pages e153-e161.
Crossref
Crossref
Y. Yamada, T. Denda, M. Gamoh, I. Iwanaga, S. Yuki, H. Shimodaira, M. Nakamura, T. Yamaguchi, H. Ohori, K. Kobayashi, M. Tsuda, Y. Kobayashi, Y. Miyamoto, M. Kotake, K. Shimada, A. Sato, S. Morita, S. Takahashi, Y. Komatsu & C. Ishioka. (2018) S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial. Annals of Oncology 29:3, pages 624-631.
Crossref
Crossref
Namju Kim, Jin Won Kim, Je-Hyun Baek, Jin-Soo Kim, Ho-Kyung Choung, Tae-Yong Kim, Kyung-Hun Lee, Yung-Jue Bang, Sang In Khwarg, Sang-Hoon Ahn, Do Joong Park, Hyung-Ho Kim, Jae-Yong Chung, Soyeon Ahn & Keun-Wook Lee. (2018) S-1–Induced Lacrimal Drainage Obstruction and Its Association with Ingredients/Metabolites of S-1 in Tears and Plasma: A Prospective Multi-institutional Study. Cancer Research and Treatment 50:1, pages 30-39.
Crossref
Crossref
Hai-ying Wang, Zhi-hua Yao, Hong Tang, Yan Zhao, Shui-ling Jin, Wen-ping Zhou, Shu-na Yao, Shu-jun Yang, Yan-yan Liu & Su-xia Luo. (2016) A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma. Oncotarget 8:5, pages 7540-7547.
Crossref
Crossref
Hideo Baba, Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Kazuhiro Yoshida, Masato Nakamura, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada & Kenichi Sugihara. (2017) S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study. ESMO Open 2:1, pages e000135.
Crossref
Crossref
Ming-ming He, Dong-sheng Zhang, Feng Wang, Zi-xian Wang, Shu-qiang Yuan, Zhi-qiang Wang, Hui-yan Luo, Chao Ren, Miao-zhen Qiu, Ying Jin, De-shen Wang, Dong-liang Chen, Zhao-lei Zeng, Yu-hong Li, Yang-yang He, Yuan-tao Hao, Pi Guo, Feng-hua Wang, Yi-xin Zeng & Rui-hua Xu. (2016) Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway. Cancer Chemotherapy and Pharmacology 79:1, pages 69-79.
Crossref
Crossref
E. Oki, A. Murata, K. Yoshida, K. Maeda, K. Ikejiri, Y. Munemoto, K. Sasaki, C. Matsuda, M. Kotake, T. Suenaga, H. Matsuda, Y. Emi, Y. Kakeji, H. Baba, C. Hamada, S. Saji & Y. Maehara. (2016) A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC). Annals of Oncology 27:7, pages 1266-1272.
Crossref
Crossref
Dan Wang, Xuejun Yu & Xiuwen Wang. (2016) High/Positive Expression of 5-Fluorouracil Metabolic Enzymes Predicts Better Response to S-1 in Patients with Gastric Cancer: A Meta-Analysis. The International Journal of Biological Markers 31:2, pages 101-109.
Crossref
Crossref
Jinyu Li, Junhao You, Wen Si, Yanyun Zhu, Yi Chen, Bo Yang, Chun Han, Ruixia Linghu, Xingyang Zhang, Shunchang Jiao & Junlan Yang. (2015) Docetaxel/S-1 Versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer. Medicine 94:41, pages e1340.
Crossref
Crossref
Chao Tu, Feng Zheng, Jin-Yu Wang, Yuan-Yuan Li & Ke-Qing Qian. (2015) An Updated Meta-analysis and System Review:is Gemcitabine+Fluoropyrimidine in Combination a Better Therapy Versus Gemcitabine Alone for Advanced and Unresectable Pancreatic Cancer?. Asian Pacific Journal of Cancer Prevention 16:14, pages 5681-5686.
Crossref
Crossref
Kazuhiro Takahashi, Yukio Oshiro, Shigeki Tsukamoto, Nobuhiro Ohkohchi & Katsu Hirayama. (2015) Acinar Cell Carcinoma of the Pancreas Successfully Controlled by IRIS: A Case Report and Literature Review. International Surgery 100:9-10, pages 1287-1294.
Crossref
Crossref
Hyun-Woo Lee, Seok-Jun Kim, Il Ju Choi, Jaewhan Song & Kyung-Hee Chun. (2015) Targeting Notch signaling by γ-secretase inhibitor I enhances the cytotoxic effect of 5-FU in gastric cancer. Clinical & Experimental Metastasis 32:6, pages 593-603.
Crossref
Crossref
MASAICHI OGAWA, MICHIAKI WATANABE, YOSHINOBU MITSUYAMA, TADASHI ANAN, MASAHISA OHKUMA, TETSUYA KOBAYASHI, KEN ETO & KATSUHIKO YANAGA. (2014) Thymidine phosphorylase mRNA expression may be a predictor of response to post-operative adjuvant chemotherapy with S-1 in patients with stage III colorectal cancer. Oncology Letters 8:6, pages 2463-2468.
Crossref
Crossref
Masato Terashima, Kazuko Sakai, Yosuke Togashi, Hidetoshi Hayashi, Marco A De Velasco, Junji Tsurutani & Kazuto Nishio. (2014) Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines. SpringerPlus 3:1.
Crossref
Crossref
M. Yoshida, M. Ishiguro, K. Ikejiri, I. Mochizuki, Y. Nakamoto, Y. Kinugasa, A. Takagane, T. Endo, H. Shinozaki, Y. Takii, H. Mochizuki, K. Kotake, S. Kameoka, K. Takahashi, T. Watanabe, M. Watanabe, N. Boku, N. Tomita, E. Nakatani & K. Sugihara. (2014) S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial). Annals of Oncology 25:9, pages 1743-1749.
Crossref
Crossref
Chunxiang Cao, Xunlei Zhang, Meng Kuang, Dongying Gu, Mingliang He, Jinfei Chen & Cuiju Tang. (2014) Survival benefit from S‐1 as compared to Fluorouracil in Asian patients with advanced gastrointestinal cancer: A meta‐analysis. Cancer Science 105:8, pages 1008-1014.
Crossref
Crossref
Raj Kumar Shukla. (2013) Recent advances in oral anticancer agents for colon cancer. Future Oncology 9:12, pages 1893-1908.
Crossref
Crossref
Toshiki Yajima, Ryoichi Onozato, Yoshinori Shitara, Akira Mogi, Shigebumi Tanaka & Hiroyuki Kuwano. (2013) Relapsed cervicomediastinal lymph node carcinoma with an unknown primary site treated with TS-1 alone: a case report. BMC Research Notes 6:1.
Crossref
Crossref
Yong Wha Moon, Soohyeon Lee, Byeong-Woo Park, Eun-Kyung Kim, Seung Il Kim, Ja Seung Koo, Seho Park, Min Jung Kim, Hyun Cheol Chung, Joo-Hang Kim & Joohyuk Sohn. (2013) S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial. BMC Cancer 13:1.
Crossref
Crossref
M. Sanford. (2013) S-1 (Teysuno®): A Review of Its Use in Advanced Gastric Cancer in Non-Asian Populations. Drugs 73:8, pages 845-855.
Crossref
Crossref
Li Tu, Weihan Zhang, Lu Ni, Zihan Xu, Kun Yang, Hongfeng Gou, Qing Zhu, Ming Liu, Yu Yang, Jian-Kun Hu & Meng Qiu. (2021) Study of SOX Combined with Intraperitoneal High-Dose Paclitaxel in Gastric Cancer with Synchronous Peritoneal Metastasis: A Phase II Single-Arm Clinical Trial. SSRN Electronic Journal.
Crossref
Crossref